Psoriasis Drugs Market Size, Share, Trends, Growth Outlook

Psoriasis Drugs Market is estimated to increase at a growth rate of 9.1% CAGR over the forecast period from 2024 to 2030.

The global Psoriasis Drugs Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Therapeutic Class (Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin-D Analogues, Others), By Treatment (Topicals, Systemic, Biologics).

An introduction to Psoriasis Drugs Market in 2024

The psoriasis drugs market is experiencing significant growth in 2024, driven by the increasing prevalence of psoriasis, advancements in targeted biologic therapies, and the expanding treatment options for moderate to severe psoriasis and psoriatic arthritis. Psoriasis drugs encompass a variety of systemic and topical medications including biologics, small molecules, and phototherapy agents, targeting inflammatory pathways, immune dysregulation, and skin cell proliferation involved in psoriasis pathogenesis. With innovations in drug development, biomarker discovery, and personalized treatment approaches, the market is witnessing continuous expansion and adoption of psoriasis drugs, offering patients improved symptom control, disease management, and long-term remission outcomes, transforming the landscape of psoriasis care and improving patient quality of life.

Psoriasis Drugs Market Trend: Growing Preference for Biologic Therapies

A significant trend in the Psoriasis Drugs Market is the increasing preference for biologic therapies over conventional treatments. Biologic drugs offer targeted mechanisms of action that inhibit specific molecules involved in the immune response, effectively managing psoriasis symptoms with fewer side effects compared to traditional systemic therapies. As more patients seek safer and more effective treatment options, the demand for biologic drugs continues to rise, driving market growth.

Psoriasis Drugs Market Driver: Rising Prevalence of Psoriasis Worldwide

The primary driver of the Psoriasis Drugs Market is the escalating prevalence of psoriasis globally. With millions of individuals affected by this chronic autoimmune skin condition, there is a growing need for effective pharmacological interventions to alleviate symptoms and improve patients' quality of life. The increasing recognition of psoriasis as a significant public health concern underscores the importance of developing innovative drugs and expanding treatment options, fueling market expansion.

Psoriasis Drugs Market Opportunity: Development of Novel Therapies and Personalized Medicine Approaches

An opportunity within the Psoriasis Drugs Market lies in the development of novel therapies and personalized medicine approaches. There is a continuous need for innovative drugs that offer improved efficacy, safety, and convenience for psoriasis patients, particularly those with moderate to severe forms of the disease. Opportunities exist for pharmaceutical companies to invest in research and development aimed at discovering new drug targets, exploring alternative treatment modalities, and leveraging personalized medicine approaches to tailor therapies to individual patient profiles. By addressing unmet medical needs and providing more tailored treatment options, companies can seize opportunities for growth and differentiation in the market.

Psoriasis Drugs Market Market Segmentation

By Therapeutic Class
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
Vitamin-D Analogues
Others
By Treatment
Topicals
Systemic
Biologics

Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Psoriasis Drugs Market Companies

AbbVie Inc
Amgen Inc
AstraZenca
Biogen Idec
Boehringer Ingelheim
Celgene Corp
Dr.Reddy`s Laboratories
Eli Lilly and Company
Forward Pharma
Janssen Biotech Inc
Leo Pharma AS
Merck and Co. Inc
Novartis AG
Pfizer Inc
Stiefel Laboratories Inc
Sunpharmaceutical Industries Ltd
Takeda Pharmaceutical Company Ltd
UCB SA
Valeant Pharmaceuticals

Reasons to Buy the Psoriasis Drugs Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Psoriasis Drugs Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Psoriasis Drugs Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Psoriasis Drugs Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Psoriasis Drugs Market Size Outlook, $ Million, 2021 to 2030
3.2 Psoriasis Drugs Market Outlook by Type, $ Million, 2021 to 2030
3.3 Psoriasis Drugs Market Outlook by Product, $ Million, 2021 to 2030
3.4 Psoriasis Drugs Market Outlook by Application, $ Million, 2021 to 2030
3.5 Psoriasis Drugs Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Psoriasis Drugs Industry
4.2 Key Market Trends in Psoriasis Drugs Industry
4.3 Potential Opportunities in Psoriasis Drugs Industry
4.4 Key Challenges in Psoriasis Drugs Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Psoriasis Drugs Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Psoriasis Drugs Market Outlook by Segments
7.1 Psoriasis Drugs Market Outlook by Segments, $ Million, 2021- 2030
By Therapeutic Class
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
Vitamin-D Analogues
Others
By Treatment
Topicals
Systemic
Biologics

8 North America Psoriasis Drugs Market Analysis and Outlook To 2030
8.1 Introduction to North America Psoriasis Drugs Markets in 2024
8.2 North America Psoriasis Drugs Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Psoriasis Drugs Market size Outlook by Segments, 2021-2030
By Therapeutic Class
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
Vitamin-D Analogues
Others
By Treatment
Topicals
Systemic
Biologics

9 Europe Psoriasis Drugs Market Analysis and Outlook To 2030
9.1 Introduction to Europe Psoriasis Drugs Markets in 2024
9.2 Europe Psoriasis Drugs Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Psoriasis Drugs Market Size Outlook by Segments, 2021-2030
By Therapeutic Class
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
Vitamin-D Analogues
Others
By Treatment
Topicals
Systemic
Biologics

10 Asia Pacific Psoriasis Drugs Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Psoriasis Drugs Markets in 2024
10.2 Asia Pacific Psoriasis Drugs Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Psoriasis Drugs Market size Outlook by Segments, 2021-2030
By Therapeutic Class
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
Vitamin-D Analogues
Others
By Treatment
Topicals
Systemic
Biologics

11 South America Psoriasis Drugs Market Analysis and Outlook To 2030
11.1 Introduction to South America Psoriasis Drugs Markets in 2024
11.2 South America Psoriasis Drugs Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Psoriasis Drugs Market size Outlook by Segments, 2021-2030
By Therapeutic Class
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
Vitamin-D Analogues
Others
By Treatment
Topicals
Systemic
Biologics

12 Middle East and Africa Psoriasis Drugs Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Psoriasis Drugs Markets in 2024
12.2 Middle East and Africa Psoriasis Drugs Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Psoriasis Drugs Market size Outlook by Segments, 2021-2030
By Therapeutic Class
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
Vitamin-D Analogues
Others
By Treatment
Topicals
Systemic
Biologics

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Amgen Inc
AstraZenca
Biogen Idec
Boehringer Ingelheim
Celgene Corp
Dr.Reddy`s Laboratories
Eli Lilly and Company
Forward Pharma
Janssen Biotech Inc
Leo Pharma AS
Merck and Co. Inc
Novartis AG
Pfizer Inc
Stiefel Laboratories Inc
Sunpharmaceutical Industries Ltd
Takeda Pharmaceutical Company Ltd
UCB SA
Valeant Pharmaceuticals
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Therapeutic Class
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
Vitamin-D Analogues
Others
By Treatment
Topicals
Systemic
Biologics